Pulmonx shares surge 25.47% intraday after hosting Paris medical event on COPD/emphysema treatments.

Pulmonx surged 25.47% intraday trading after announcing a medical event in Paris on March 26 focused on chronic obstructive pulmonary disease (COPD) and endoscopic emphysema treatments. The event, featuring a presentation by Dr. Gaëlle Weisenburger on endoscopic therapies, highlights the company’s advancements in respiratory care, including the Chartis Precision XL catheter and Zephyr Valves. These developments underscore Pulmonx’s commitment to innovating COPD and emphysema management, likely driving investor optimism about its product pipeline and market position. The event, targeted at pulmonologists, reinforces the company’s strategic focus on clinical education and adoption of its technologies, aligning with the stock’s sharp intraday gain.